Find and Pitch Jounalists, Get Your Story Covered

Tags: metformin dementia opioid methadone tobacco

	Profile	Recent Articles on Subject
1	Crystal Phend MedPage Today Contributing editor at MedPage Today. Personal views. HealthcareEditing	SGLT2i Improves Outcomes After TAVI - 5 days ago Wegovy Helps HFpEF Patients With Diabetes Mellitus - 12 months ago Weight-Loss Drug Benefit Spans HFpEF, HFmrEF - over 1 year ago
2	Allison DeAngelis STAT News Reporter at STAT. Formerly Insider, BBJ. biopharmastartupsventure capital	STAT+: Novo Nordisk sets sights on new type of oral obesity drug - 6 days ago STAT+: Eli Lilly reports tirzepatide MASH success during Q4 earnings - about 1 year ago
3	Elaine Chen STAT News Reporter at STATnews. Formerly at Business Insider. Chicago, Illinois journalism	STAT+: Novo Nordisk sets sights on new type of oral obesity drug - 6 days ago STAT+: With new Wegovy data in hand, Novo Nordisk will file for approval in MASH - 5 months ago STAT+: Lilly’s Zepbound slashed risk of developing diabetes - 8 months ago STAT+: Positive trial results set up obesity drug Wegovy for use against heart failure - 12 months ago
4	Frank Vinluan MedCity News Medical innovation tracker. MedCity, USA medicalinnovation	Novo Nordisk Bets $200M on Triple-Targeting Drug for Obesity and Other Metabolic Diseases - 10 days ago
5	Kristen Monaco MedPage Today	SGLT1/2 Inhibitor Cut Stroke, Heart Attack Risk in Diabetic Kidney Disease - about 2 months ago Imcivree Label Expanded; Weight Loss With Weekly Injection; Kidney Donation Chain - 3 months ago Zepbound Can Prevent Diabetes; Menopause and Cognition; Tandem's Insulin Pump Update - 8 months ago Early-Stage GLP-1 Win in Obesity; An Argument for BMI's Value; Insulin Supply Issues - 8 months ago FDA Approves First-Ever Drug for Serious Liver Condition - about 1 year ago One Class of Antidiabetic Linked With Lower Kidney Stone Risk - about 1 year ago Breast Cancer Drug Repurposed for Infant With Congenital Hyperinsulinism - about 1 year ago In Acute Kidney Disease, SGLT2 inhibitors Were All-Around Protective - about 1 year ago Phase II Wins, Losses for Obesity Drugs; More Positive Veozah Data; Walking Off T2D - over 1 year ago Methotrexate Tied to Greater Risks for Older Patients With CKD - over 1 year ago Mounjaro vs Ozempic for Obesity; New Microwave Ablation System; GAHT Erythrocytosis - over 1 year ago Glucose Supplement Recalled; ADA Sued by Former Employee; Forteo Generic OK'd - over 1 year ago Another Study Highlights Metformin's Dementia Protection Properties - over 1 year ago Hospitalizations With Fake Ozempic; Vosoritide OK'd for All Ages; Mounjaro for Kids? - over 1 year ago Farxiga Cuts A1c in Pediatric Diabetes; Late-Stage CAH Win; At-Home Menopause Test - over 1 year ago Smoking-Related Metabolic Changes Partly Drive Type 2 Diabetes Risk - over 1 year ago Faster-Acting Insulin Aspart Safe for Pregnant Women With Diabetes - over 1 year ago
6	Amy Baxter Pharma Voice Scientist, inventor, former pediatrician. Atlanta, Georgia pain relieftechnologyinnovation	Beyond GLP-1s? This biotech is exploring longer-term metabolic treatments - about 2 months ago To penetrate crowded GLP-1 field, Rivus Pharma is taking a metabolic approach - about 1 year ago
7	Ed Silverman STAT News Pharmalot columnist. Senior writer at STATnews. pharmaceutical industry	STAT+: Pharmalittle: We’re reading about a Merck deal for an obesity pill, a departing FDA official, and more - 4 months ago STAT+: Pharmalittle: We’re reading about a Merck drug-label controversy, Astellas pulling an application, and more - 5 months ago STAT+: Pharmalittle: We’re reading about Zepbound trial results, an Alnylam heart drug, and more - 8 months ago STAT+: Pharmalittle: We’re reading about Roche obesity drug data, fallout from the Menendez verdict, and more - 9 months ago STAT+: Pharmalittle: We’re reading about a Pfizer daily weight loss pill, a Novo Nordisk setback, and more - 9 months ago STAT+: Pharmalittle: We’re reading about Wegovy approved for heart risks, an ALS drug puzzle, and more - about 1 year ago STAT+: Pharmalittle: We’re reading about Ozempic tackling kidney disease, OTC birth control, and more - about 1 year ago STAT+: Pharmalittle: More U.S. states and cities are suing insulin makers; Biden looks to boost U.S. drug manufacturing amid shortages - over 1 year ago STAT+: Pharmalittle: Lilly wins FDA approval for a weight-loss drug; AstraZeneca enters the race for an obesity pill - over 1 year ago STAT+: Pharmalittle: Sarepta Duchenne therapy misses primary endpoint; FDA holds panel for first CRISPR treatment for sickle cell - over 1 year ago STAT+: Pharmalittle: Novo halts Ozempic kidney failure trial after early signs of success; GSK settles California Zantac lawsuit - over 1 year ago
8	Marissa Plescia MedCity News Reporter at MedCity News. reportingjournalism	Noom Launches Oral Medication Offering for Weight Loss - 4 months ago
9	Ian Ingram MedPage Today Deputy Managing Editor. MedPage Today. New York, New York medical journalismediting	GLP-1 Drugs Tied to Reduced Risk of Dangerous Blood Clots - 4 months ago
10	The Conversation Science Alert Science news. Official account. Australia science news	Ozempic vs Supplements: Dietitian Reveals Truth About GLP-1 Imitations - 4 months ago

Journalists covering metformin